AMS acquires Raleigh in £22m woundcare acquisition – Med-Tech Innovation

Superior Medical Options (AMS), a surgical and superior woundcare specialist has acquired Raleigh Adhesive Coatings, an unbiased woundcare and bio-diagnostics coatings enterprise for £22 million in money.

The acquisition goals to strengthen AMS’s place within the woundcare sector by bringing in-house specialist companies of acrylic and silicone coating, perforation processing and a few bulk supplies changing capabilities that are presently outsourced. Silicone coating and perforation capabilities are notably necessary to AMS as they’re intrinsic to all trendy superior woundcare foam dressings. Raleigh is an current key provider, producing the coated adhesive mesh used within the new LiquiBand XL gadget.

The Acquisition brings synergies with AMS’s completed product providing, with the chance to extend the effectivity of the corporate’s woundcare manufacturing operations and supply entry factors into new prospects and markets, cross-selling of services in addition to an R&D pipeline of recent initiatives within the medical house.

Chris Meredith, CEO of AMS, mentioned: “We’re delighted so as to add Raleigh to the Group. We’ve got been searching for synergistic applied sciences that add worth to our woundcare enterprise and this acquisition strengthens our place and product providing in that sector considerably. Having outsourced silicone coating and perforation for a while, we’re happy to carry this functionality in-house. Raleigh has additionally performed an necessary half in bettering the design of our LiquiBandXL mesh which we see as an necessary a part of our continued US progress technique. Raleigh’s experience in different sectors equivalent to bio-diagnostic strips additionally opens up additional new business alternatives for the Group. We sit up for welcoming the Raleigh workforce to the Group to construct on their business success and leverage their improvement pipeline.”

Raleigh provides acrylic and silicone gel contract coating for the woundcare market. It provides a package deal of companies to its prospects via its three separate coating traces (one solvent primarily based, one silicone gel primarily based, and one specialist industrial coating line), its pilot facility, two slitting traces, changing traces in addition to a stand-alone perforation unit all of which have vital capability headroom.

Raleigh gives tailored options for its blue-chip buyer base, which incorporates lots of the main woundcare producers and different specialist producers and suppliers within the healthcare sector, and has a powerful pipeline of modern developments.

Jonathan Saunders, chairman of Apollo Chemical substances Group and majority shareholder of Raleigh, mentioned: “The synergies between AMS and Raleigh make this a really optimistic and thrilling time for all at Raleigh. We’ve got invested in creating applied sciences over the past 5 years for the woundcare and bio-diagnostic markets and have a terrific workforce which has labored exhausting to determine our popularity for excellence, service and high quality inside these specialist fields. The medical sector doesn’t naturally match with Apollo Chemical substances’ experience and so I’m delighted to say AMS gives a superb alternative for each companies to enhance one another, present enhanced product choices and speed up our joint success. We sit up for watching the enterprise go from energy to energy.”